DDInter255 DDInter1676
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Busulfan {u} (Compound) treats {v} (Disease) hematologic cancer
Busulfan {u} (Compound) binds {v} (Gene) MGST2
Busulfan {u} (Compound) upregulates {v} (Gene) DUSP11
Busulfan {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Busulfan {u} (Compound) downregulates {v} (Gene) MRPL19
Busulfan {u} (Compound) causes {v} (Side Effect) Dermatitis bullous
Busulfan (Compound) treats hematologic cancer (Disease)
Busulfan (Compound) binds MGST2 (Gene)
Busulfan (Compound) upregulates DUSP11 (Gene)
Busulfan (Compound) is included by Alkylating Activity (Pharmacologic Class)
Busulfan (Compound) downregulates MRPL19 (Gene)
Busulfan (Compound) causes Dermatitis bullous (Side Effect)